Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich

Acta Oncol. 2005;44(6):529-36. doi: 10.1080/02841860510029923.

Abstract

We analyzed characteristics, therapy and outcome of patients with bilateral testicular germ cell tumor (TGCT) at our institutions. Among 1,180 TGCT patients diagnosed and/or treated between 1979 and 2003, 47 (4.0%) developed a second TGCT. Nine of 14 patients (64%) with synchronous TGCT are alive with no evidence of disease (NED) at a median follow-up of 37 months. Thirty-three patients had a metachronous bilateral TGCT. Median time to the 2(nd) TGCT was 71 months. At diagnosis of 2(nd) TGCT 30 patients had stage I, 1 had stage II and 2 had stage III disease. Thirty-two of 33 patients are alive with NED at a median follow up of 41 months. No patient died from second TGCT. As a review of the literature confirms our data we do not recommend a routine biopsy of the contralateral testicle for early detection of testicular intraepithelial neoplasia (TIN).

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Biopsy
  • Combined Modality Therapy
  • Humans
  • Male
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / therapy*
  • Neoplasms, Multiple Primary / pathology
  • Neoplasms, Multiple Primary / therapy*
  • Neoplasms, Second Primary / pathology
  • Neoplasms, Second Primary / therapy*
  • Orchiectomy
  • Prognosis
  • Seminoma / pathology
  • Seminoma / therapy
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / therapy*
  • Testis / pathology
  • Testis / surgery
  • Treatment Outcome